title: Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions.
abstract: Direct in vivo gene delivery is a prerequisite for many gene therapy strategies; however, efficacy has been limited by a lack of therapeutic gene transfer. In studying intrapleural malignancy as a model for the gene therapy of non-small cell lung cancer, we previously identified soluble chondroitin sulfate-proteoglycans/glycosaminoglycans (CS-PG/GAGs) in malignant pleural effusions (MPE) as factors that inhibit retroviral vector (RV) transduction. Similarly, we have observed inhibition to gene transfer in the fluid component of MPE using adenoviral (Ad) vectors. Analyses indicate that the factors responsible for the block are filterable, soluble, titrable, and heat stable (56 degrees C). Passage through microporous membranes fractionates the inhibitory factors into large (> 100 kD) components of the effusions. In contrast to RV transduction, hyaluronic acid or CS-PG/GAGs are not the inhibitors because the block is not reversed by pretreatment of the effusions with mammalian hyaluronidase, and exogenous addition of GAGs into the transduction media does not diminish Ad transduction. In considering the mechanism of action of the inhibitory factors, we observe that Ad entry, and specifically the binding of radiolabeled Ad to its target cell, is inhibited in the presence of MPE. Ad internalization may also be impaired; however, these studies exclude soluble fibronectin in MPE as a competitive inhibitor of Ad transduction. Lastly, sepharose A- mediated immunoglobulin depletion of MPE only partially reverses the block, and significant inhibition to Ad gene transfer persists at lower adenovirus:target cell ratios. Identifying the structural and functional basis for inhibition to Ad gene transfer may yield specific strategies to enable better in vivo translation of gene therapy approaches.
authors.affiliation: Department of Medicine and the UCLA/Wadsworth Pulmonary Immunology Laboratory, University of California at Los Angeles, Veterans Administration-Greater Los Angeles Health Care System, Los Angeles, California 90073, USA. rbatra@ucla.edu
authors.forename: R K
authors.initials: RK
authors.lastname: Batra
authors.forename: S M
authors.initials: SM
authors.lastname: Dubinett
authors.forename: B W
authors.initials: BW
authors.lastname: Henkle
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: B K
authors.initials: BK
authors.lastname: Gardner
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung; D016326:Extracellular Matrix Proteins / Q000737:chemistry; D018014:Gene Transfer Techniques; D017930:Genes, Reporter; D015316:Genetic Therapy; D006025:Glycosaminoglycans / Q000494:pharmacology; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology; D008175:Lung Neoplasms; D016066:Pleural Effusion, Malignant / Q000737:chemistry* / Q000145:classification / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D016326:Extracellular Matrix Proteins; D006025:Glycosaminoglycans; D006821:Hyaluronoglucosaminidase